{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:05:21Z","timestamp":1790111121611,"version":"4.0.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.06.004","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:23:11Z","timestamp":1781954591000},"page":"827-831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Obesity in adults with cystic fibrosis following prescription of elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1016","volume":"25","author":[{"given":"Joshua S.","family":"Ostrenga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-8505","authenticated-orcid":false,"given":"Christina M.","family":"Mingora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4616-7426","authenticated-orcid":false,"given":"Sylvia","family":"Szentpetery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-7374","authenticated-orcid":false,"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-3767","authenticated-orcid":false,"given":"Michael S.","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cromwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Flume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jcf.2026.06.004_bib0001","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.004_bib0002","unstructured":"Foundation, C.F., Cystic Fibrosis Foundation Patient Registry Annual Data Report. 2024: Bethesda, MD."},{"issue":"19","key":"10.1016\/j.jcf.2026.06.004_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.06.004_bib0004","article-title":"The changing landscape of treatment for cystic fibrosis related diabetes","volume":"35","author":"Amini","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"2","key":"10.1016\/j.jcf.2026.06.004_bib0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2026.06.004_bib0006","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The cystic fibrosis foundation patient registry. Design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"26","key":"10.1016\/j.jcf.2026.06.004_bib0008","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMp1802313","article-title":"Making neighborhood-disadvantage metrics accessible - the neighborhood atlas","volume":"378","author":"Kind","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.06.004_bib0009","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jcf.2025.08.017","article-title":"Identifying cystic fibrosis programs in the United States with disproportionately disadvantaged patient populations: methodology and implications for care","volume":"24","author":"Oates","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.06.004_bib0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jcf.2024.10.009","article-title":"Aging with CF: characteristics of people with CF aged 40 and older in the United States","volume":"24","author":"Ostrenga","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.06.004_bib0011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jcf.2024.09.022","article-title":"Development of metabolic syndrome in people with cystic fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Ratti","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"6 Pt 2","key":"10.1016\/j.jcf.2026.06.004_bib0012","article-title":"Sociodemographic disparities in obesity prevalence among adults aged 20-59 years between 2017 and 2023","volume":"4","author":"Agboola","year":"2025","journal-title":"JACC Adv"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:07:17Z","timestamp":1790107637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326016450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1569199326016450"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity in adults with cystic fibrosis following prescription of elexacaftor\/tezacaftor\/ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}